Smith Group Asset Management LLC Has $18.76 Million Stock Position in Johnson & Johnson $JNJ

Smith Group Asset Management LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,823 shares of the company’s stock after purchasing an additional 1,986 shares during the period. Smith Group Asset Management LLC’s holdings in Johnson & Johnson were worth $18,761,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. FSM Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 107.4% during the 2nd quarter. FSM Wealth Advisors LLC now owns 8,453 shares of the company’s stock valued at $1,313,000 after acquiring an additional 4,378 shares during the last quarter. Gill Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 4.6% during the 2nd quarter. Gill Capital Partners LLC now owns 2,365 shares of the company’s stock valued at $361,000 after acquiring an additional 103 shares during the last quarter. Hoge Financial Services LLC increased its holdings in shares of Johnson & Johnson by 6.3% during the 2nd quarter. Hoge Financial Services LLC now owns 1,381 shares of the company’s stock valued at $211,000 after acquiring an additional 82 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Bleakley Financial Group LLC now owns 112,363 shares of the company’s stock valued at $17,163,000 after acquiring an additional 1,543 shares during the last quarter. Finally, Castle Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 3.4% during the 2nd quarter. Castle Wealth Management LLC now owns 4,800 shares of the company’s stock valued at $733,000 after acquiring an additional 156 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $192.31 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $463.15 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The business has a 50 day simple moving average of $181.99 and a 200 day simple moving average of $165.84.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Loop Capital set a $190.00 target price on Johnson & Johnson in a report on Wednesday. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.